The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies
Abstract
Background: Multiple metrics evaluate the efficacy of psoriasis treatment, but interestingly, the correlation between the mostly widely used clinical trial efficacy end point, the physician‐rendered Psoriasis Area Severity Index PASI score and, the most widely used quality of life metric, the Dermatology Life Quality Index DLQI, is not always high. Objective: To perform a systematic review to determine PASI to DLQI correlation. Methods: RCT s of biological agents for the treatment of moderate‐to‐severe psoriasis were reviewed in accordance with PRISMA guidelines. The mean percentage PASI improvement and change in mean DLQI values were recorded and compared for treatment groups from baseline to 10–16 weeks of therapy. Results: A search of the literature yielded 155 sources, of which 13 RCT s met inclusion and exclusion criteria. Percentage of PASI improvement from baseline correlates with DLQI changes with an r2 value of 0.80 from baseline through weeks 10–16. When grouped by mean percentage reduction in PASI, agents demonstrating >75% mean reduction in PASI demonstrated a mean DLQI improvement over agents that achieved <75%–50% mean reduction in PASI or <50% mean reduction in PASI [minimal clinically important difference (MCID) 3.2]. In addition, a reduction in mean PASI of at least 75%, predicted a mean movement from DLQI band 3 to DLQI band 1, in all nine treatment arms demonstrating such efficacy. Conclusions: Mean PASI and DLQI correlate predictably in patients with chronic moderate‐to‐severe plaque psoriasis undergoing treatment with biological agents. A reduction in PASI of at least 75% can translate to significant quality‐of‐life improvement in patients treated with these therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Self-citationPapp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Psoriasis: epidemiology, clinical features, and quality of life
Langley, R. G. B., Krueger, G. G., & Griffiths, C. E. M. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.033217 · Cited by 1,115
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Prevalence of cardiovascular risk factors in patients with psoriasis
Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., Troxel, A. B., & Gelfand, J. M. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.08.040 · Cited by 1,010
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Self-citationHongbo, Y., Thomas, C. L., Harrison, M. A., Sam Salek, M., & Finlay, A. Y. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23621.x · Cited by 854
Basra, M. K. A., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08832.x · Cited by 789
Papp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case?control study
Gisondi, P., Tessari, G., Conti, A., Piaserico, S., Schianchi, S., Peserico, A., Giannetti, A., & Girolomoni, G. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07986.x · Cited by 675
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis
Sommer, D. M., Jenisch, S., Suchan, M., Christophers, E., & Weichenthal, M. (2006) · Archives of Dermatological Research · doi:10.1007/s00403-006-0703-z · Cited by 667
Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582
Gordon, K. B., Langley, R. G., Leonardi, C., Toth, D., Menter, M. A., Kang, S., Heffernan, M., Miller, B., Hamlin, R., Lim, L., et al. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.05.027 · Cited by 510
Kimball, A. B., Gladman, D., Gelfand, J. M., Gordon, K., Horn, E. J., Korman, N. J., Korver, G., Krueger, G. G., Strober, B. E., & Lebwohl, M. G. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.01.006 · Cited by 432
Self-citationEfalizumab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial
Gordon, K. B., Papp, K. A., Hamilton, T. K., Walicke, P. A., Dummer, W., Li, N., Bresnahan, B. W., Menter, A., & for the Efalizumab Study Group (2003) · JAMA · doi:10.1001/jama.290.23.3073 · Cited by 391
Gupta, M. A., & Gupta, A. K. (2003) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200304120-00003 · Cited by 371
The contribution of perceptions of stigmatisation to disability in patients with psoriasis
Richards, H. L., Fortune, D. G., Griffiths, C. E. M., & Main, C. J. (2001) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(00)00210-5 · Cited by 298
Augustin, M., Krüger, K., Radtke, M. A., Schwippl, I., & Reich, K. (2008) · Dermatology · doi:10.1159/000119415 · Cited by 271
Association between Psoriasis and the Metabolic Syndrome
Cohen, A. D., Sherf, M., Vidavsky, L., Vardy, D. A., Shapiro, J., & Meyerovitch, J. (2008) · Dermatology · doi:10.1159/000111512 · Cited by 268
SUICIDAL IDEATION IN PSORIASIS
GUPTA, M. A., SCHORK, N. J., GUPTA, A. K., KIRKBY, S., & ELLIS, C. N. (1993) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1993.tb02790.x · Cited by 265
Quantifying the harmful effect of psoriasis on health-related quality of life
Weiss, S. C., Kimball, A. B., Liewehr, D. J., Blauvelt, A., Turner, M. L., & Emanuel, E. J. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.122755 · Cited by 265
Self-citationPsoriasis and the Risk of Diabetes and Hypertension: A Prospective Study of US Female Nurses
Qureshi, A. A., Choi, H. K., Setty, A. R., & Curhan, G. C. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.48 · Cited by 250
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis
Gisondi, P., Targher, G., Zoppini, G., & Girolomoni, G. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.020 · Cited by 225
Langley, R. G., Feldman, S. R., Han, C., Schenkel, B., Szapary, P., Hsu, M.-C., Ortonne, J.-P., Gordon, K. B., & Kimball, A. B. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.09.014 · Cited by 218
Self-citationIncreased occurrence of psoriasis in patients with Crohn's disease and their relatives.
Lee, F. I., Bellary, S. V., & Francis, C. Y. (1990) · PubMed · Cited by 218
Menter, A. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.1.31 · Cited by 211
Shikiar, R., Willian, M. K., Okun, M. M., Thompson, C. S., & Revicki, D. A. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-71 · Cited by 210
Revicki, D., Willian, M. K., Saurat, J.-H., Papp, K. A., Ortonne, J.-P., Sexton, C., & Camez, A. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08236.x · Cited by 168
Dubertret, L., Sterry, W., Bos, J. D., Chimenti, S., Shumack, S. P., Larsen, C. G., Shear, N. H., Papp, K. A., & CLEAR Multinational Study Group (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07344.x · Cited by 143
Krueger, G. G., Langley, R. G. B., Finlay, A. Y., Griffiths, C. E. M., Woolley, J. M., Lalla, D., & Jahreis, A. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06948.x · Cited by 136
Reich, K., Nestle, F. O., Papp, K. A., Ortonne, J. ‐., Wu, Y., BALA, M. M., Evans, R., Guzzo, C. A., Li, S., Dooley, L. T., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07237.x · Cited by 131
The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort
McKenna, K. E., & Stern, R. S. (1997) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(97)80214-9 · Cited by 119
Revicki, D. A., Willian, M. K., Menter, A., Gordon, K. B., Kimball, A. B., Leonardi, C. L., Langley, R. G. B., Kimel, M., & Okun, M. M. (2007) · Journal of Dermatological Treatment · doi:10.1080/09546630701646172 · Cited by 102
Self-citationThe psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization
Perrott, S. B., Murray, A. H., Lowe, J., & Mathieson, C. M. (2000) · Physiology & Behavior · doi:10.1016/s0031-9384(00)00290-0 · Cited by 94
Feldman, S. R., Kimball, A. B., Krueger, G. G., Woolley, J. M., Lalla, D., & Jahreis, A. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.06.053 · Cited by 83
Self-citationReich, K., Segaert, S., van de Kerkhof, P., Durian, C., Boussuge, M. P., Paolozzi, L., Wajdula, J. S., & Boggs, R. L. (2009) · Dermatology · doi:10.1159/000237871 · Cited by 63
Cited by
Thaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551
Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
Lynde, C. W., Poulin, Y., Vender, R., Bourcier, M., & Khalil, S. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.036 · Cited by 335
Metadata
- Authors
- Mattei, P. L., Corey, K. C., & Kimball, A. B.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2013-02-21
- Volume
- 28
- Issue
- 3
- Pages
- 333-337
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W1996308907
- Cited by
- 358
- References
- 38
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.